| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.24% | 86.11% | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 88.65% | 93.16% |
| Operating Margin | 34.77% | -2.11% | 38.83% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.23% | -119.30% |
| EBITDA Margin | 36.52% | -0.23% | 40.66% | 49.89% | 38.39% | 47.79% | 31.34% | 23.22% | 7.42% | 4.19% | -39.19% | -108.40% |
| Net Margin | 32.94% | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -53.89% | -127.25% |
| Current Ratio | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 | 2.78 | 4.20 |
| Quick Ratio | 2.46 | 2.35 | 3.78 | 4.66 | 4.30 | 4.18 | 3.49 | 3.32 | 3.14 | 2.21 | 2.67 | 4.12 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | 21.18% | -3.26% | 20.59% | 23.88% | 23.19% | 31.22% | 19.34% | 47.28% | 12.90% | -8.37% | -50.87% | -67.38% |
| ROA | 15.42% | -2.38% | 15.92% | 18.30% | 17.44% | 23.07% | 14.15% | 33.57% | 7.43% | -3.87% | -22.26% | -31.63% |
| Asset Turnover | 0.47 | 0.49 | 0.43 | 0.49 | 0.56 | 0.53 | 0.50 | 0.49 | 0.70 | 0.59 | 0.41 | 0.25 |
| Book Value / Share | 72.35 | 63.63 | 67.49 | 53.70 | 38.86 | 32.98 | 23.34 | 17.11 | 8.07 | 5.47 | 4.53 | 4.66 |
Vertex Pharmaceuticals Incorporated is a global biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the discovery, development, and commercialization of transformative medicines for patients with serious diseases. The company's primary focus centers on cystic fibrosis, where it has developed a portfolio of CFTR modulators that target the underlying genetic cause of the disease rather than merely treating symptoms. Beyond cystic fibrosis, Vertex advances therapies for hemoglobinopathies including sickle cell disease and transfusion-dependent beta thalassemia through gene-editing and cell therapy approaches. The company's pipeline also encompasses treatments for acute pain, myotonic dystrophy type 1, type 1 diabetes, autosomal dominant polycystic kidney disease, and APOL1-mediated kidney disease. Vertex maintains research and development, manufacturing, and commercial operations across North America, Europe, and international markets, distributing its products through specialty pharmacies, wholesalers, hospitals, and clinics. The company leverages collaborations with leading research institutions and biotechnology partners to expand its therapeutic capabilities and bring innovative treatment options to patients with rare and serious conditions.